Recent News

• 09.15.2025 - InspiroGene by McKesson Selected as the Specialty Pharmacy Partner for Iovance’s Amtagvi®—First Cell Therapy Approved for Solid Tumors
• 09.09.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.05.2025 - 2025 Wells Fargo Healthcare Conference
• 08.29.2025 - Iovance Biotherapeutics to Present at Upcoming Conferences
• 08.29.2025 - Iovance Biotherapeutics to Present at Upcoming Conferences
• 08.22.2025 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 08.22.2025 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 08.18.2025 - Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma
• 08.18.2025 - Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

Recent Filings

• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.29.2025 - 8-K Current report
• 08.29.2025 - EX-99.1 EX-99.1
• 08.22.2025 - 8-K Current report
• 08.22.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 08.19.2025 - EX-99.1 EX-99.1
• 08.19.2025 - 8-K Current report